Avertto is developing the first patented, non-invasive continuous carotid hemodynamic monitor for early detection of acute cerebrovascular events in ICU and high-risk patients. Published multicenter results showed 100% sensitivity and 86% specificity. FDA Class I and Israeli MoH registered, Avertto is now preparing for its first U.S. clinical trial.